Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN : L85195TG1984PLC004507 | |
| Tel : +91 40 4900 2900 | |
| Fax : +91 40 4900 2999 | |
| Email : mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 | Fax Nos.: 022-26598120/ 26598237 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
This is in reference to our intimation
dated January 15, 2019 wherein we informed you about completion of USFDA audit and issuance of a Form 483 with 4 (four) observations
at our Formulations Srikakulam Plant (SEZ) Unit I, Andhra Pradesh.
In this regard, we would like to inform
you now that we have received a written communication from the US FDA that the aforesaid inspection has been classified as Voluntary
Action Initiated (VAI).
This is for your information.
| With regards, | |
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)